Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

Código QR

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus

Jason Seewoodhary1, Leanne Griffin1, Stephen C Bain11Department of Diabetes and Endocrinology, Swansea School of Medicine, University of Wales, Swansea SA2 8PP, UKAbstract: Exenatide (also known as exendin-4) is a glucagon-like peptide-1 mimetic, which is indicated for the treatment of type 2 diabet...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Seewoodhary J, Griffin, Bain S
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Type 2 Diabetes Exenatide QW GLP-1 mimetic HbA1C Weight loss Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/bad96351b7d74267b44ac891c70c9d99
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

An indirect comparison of HbA1c treatment effect with albiglutide and exenatide 2.0 mg QW using the Bucher method
por: Martin AA, et al.
Publicado: (2016)

Critical appraisal of once-weekly formulation of exenatide in the control of type 2 diabetes mellitus
por: Jason Seewoodhary, et al.
Publicado: (2010)

Real-world glycemic outcomes in patients with type 2 diabetes initiating exenatide once weekly and liraglutide once daily: a retrospective cohort study
por: Saunders WB, et al.
Publicado: (2016)

New indications for exenatide therapy of type 2 diabetes mellitus
por: Olga Konstantinovna Vikulova, et al.
Publicado: (2010)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)

Weight Loss Outcomes Among Early High Responders to Exenatide Treatment: A Randomized, Placebo Controlled Study in Overweight and Obese Women
por: Megan Rodgers, et al.
Publicado: (2021)

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Knop FK, et al.
Publicado: (2010)

Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud A, et al.
Publicado: (2015)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao Q, et al.
Publicado: (2016)

Exenatide extended-release: a once weekly treatment for patients with type 2 diabetes
por: Mann KV, et al.
Publicado: (2014)

Exenatide once weekly: sustained improvement in glycemic control and cardiometabolic measures through 3 years
por: MacConell L, et al.
Publicado: (2013)

Clinical Impact of Liraglutide as a Treatment of Obesity
por: Alruwaili H, et al.
Publicado: (2021)

Pharmalogical effects and results of clinical trials of the first incretinomimetic exenatide
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients
por: MacConell L, et al.
Publicado: (2015)

Unexpected bleeding after Exenatide treatment: a causative relationship or a coincidence?
por: Khoury Johad, et al.
Publicado: (2018)

Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data
por: Kugler AJ, et al.
Publicado: (2018)

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
por: Reed J, et al.
Publicado: (2021)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
por: Lee SP, et al.
Publicado: (2019)

BH3-mimetics: recent developments in cancer therapy
por: Paul A. Townsend, et al.
Publicado: (2021)

New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin
por: Gallwitz B
Publicado: (2010)

Efficacy of bariatric surgery in improving metabolic outcomes in patients with diabetes. A 24-month follow-up study from a single center in the UAE
por: Alnageeb H, et al.
Publicado: (2018)

Weight loss medications in Canada – a new frontier or a repeat of past mistakes?
por: Wharton S, et al.
Publicado: (2017)

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
por: Alina Babenko, et al.
Publicado: (2014)

Preparation of exenatide-loaded linear poly(ethylene glycol)-brush poly(L-lysine) block copolymer: potential implications on diabetic nephropathy
por: Tong F
Publicado: (2017)

Long-term management of type 2 diabetes with glucagon-like peptide-1 receptor agonists
por: Courtney H, et al.
Publicado: (2017)

Dual GIP–GLP1-Receptor Agonists In The Treatment Of Type 2 Diabetes: A Short Review On Emerging Data And Therapeutic Potential
por: Bastin M, et al.
Publicado: (2019)

The hermeneutical dimension of the bioethical enterprise. Notes on the dialogical/narrative foundations of bioethics
por: Lolas Stepke,Fernando
Publicado: (2018)

Past, present, and future: Critical analysis of use of gastric bands in obese patients
por: Snyder B, et al.
Publicado: (2010)

Smartphone applications to aid weight loss and management: current perspectives
por: Sutton EF, et al.
Publicado: (2016)

Medications that cause weight gain and alternatives in Canada: a narrative review
por: Wharton S, et al.
Publicado: (2018)

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Teshome G, et al.
Publicado: (2020)

Tackling obesity: new therapeutic agents for assisted weight loss
por: McFarlane S
Publicado: (2010)

SGLT2 Inhibitors as Add-On Therapy to Metformin for People with Type 2 Diabetes: A Review of Placebo-Controlled Trials in Asian versus Non-Asian Patients
por: Scheen AJ
Publicado: (2020)

Critical appraisal of the safety and efficacy of insulin detemir in glycemic control and cardiovascular risk management in diabetics
por: Le Floch J
Publicado: (2010)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
por: Liu F, et al.
Publicado: (2020)

Ion- and osmoregulating renal functions in patients with type 2 diabetes mellitus
por: Evgeniya Vladimirovna Balbotkina, et al.
Publicado: (2016)

Personalized multistep cognitive behavioral therapy for obesity
por: Dalle Grave R, et al.
Publicado: (2017)

Association of diabetes knowledge with glycemic control and self-care practices among Pakistani people with type 2 diabetes mellitus
por: Bukhsh A, et al.
Publicado: (2019)

Predictors of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors in Taiwanese Patients with Type 2 Diabetes Mellitus
por: Lin YH, et al.
Publicado: (2019)